Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway.

Zhang F, Shang D, Zhang Y, Tian Y.

PLoS One. 2011;6(5):e20382. doi: 10.1371/journal.pone.0020382. Epub 2011 May 23.

2.

Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.

Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O, Kojima Y.

Eur J Cancer. 2013 May;49(7):1715-24. doi: 10.1016/j.ejca.2012.11.038. Epub 2012 Dec 27.

PMID:
23274199
4.

Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.

Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ.

Clin Cancer Res. 1998 Dec;4(12):2957-66.

5.
6.

IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos.

Furukawa M, Takaishi H, Takito J, Yoda M, Sakai S, Hikata T, Hakozaki A, Uchikawa S, Matsumoto M, Chiba K, Kimura T, Okada Y, Matsuo K, Yoshida H, Toyama Y.

J Immunol. 2009 Aug 15;183(4):2397-406. doi: 10.4049/jimmunol.0802091. Epub 2009 Jul 20.

7.

NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.

Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T.

Br J Cancer. 2010 Mar 2;102(5):873-82. doi: 10.1038/sj.bjc.6605574. Epub 2010 Feb 16.

9.

IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3.

Owaki T, Asakawa M, Kamiya S, Takeda K, Fukai F, Mizuguchi J, Yoshimoto T.

J Immunol. 2006 Mar 1;176(5):2773-80.

10.

Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.

Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, Liu Z.

PLoS One. 2013 May 17;8(5):e62823. doi: 10.1371/journal.pone.0062823. Print 2013.

11.

MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.

Zhu Y, Jiang H, Zhang C, He QJ, Yang B, Li LJ, Zhu H.

Pharmazie. 2009 Dec;64(12):823-8.

PMID:
20095141
12.

Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells.

Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH.

Cancer Sci. 2008 May;99(5):905-13. doi: 10.1111/j.1349-7006.2008.00756.x. Epub 2008 Feb 18.

13.

IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms.

Lucas S, Ghilardi N, Li J, de Sauvage FJ.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15047-52. Epub 2003 Dec 1.

14.

Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells.

Liu L, Meng J, Zhang C, Duan Y, Zhao L, Wang S, Shan B.

Oncol Rep. 2012 May;27(5):1497-503. doi: 10.3892/or.2012.1663. Epub 2012 Jan 27.

PMID:
22293948
15.

Antiproliferative activity of IL-27 on melanoma.

Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J.

J Immunol. 2008 May 15;180(10):6527-35.

16.

Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer.

Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M.

Cancer Sci. 2011 Nov;102(11):1977-90. doi: 10.1111/j.1349-7006.2011.02079.x. Epub 2011 Oct 10.

17.

Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.

Usui E, Nishii K, Katayama N, Lorenzo V F, Chen F, Monma F, Otsuki T, Shiku H.

Hematol J. 2004;5(6):505-12.

PMID:
15570293
18.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

19.

Interferon-α induces G1 cell-cycle arrest in renal cell carcinoma cells via activation of Jak-Stat signaling.

Shang D, Yang P, Liu Y, Song J, Zhang F, Tian Y.

Cancer Invest. 2011 Jun;29(5):347-52. doi: 10.3109/07357907.2011.568566.

PMID:
21599510
20.

IFN-gamma-induced SOCS-1 regulates STAT6-dependent eotaxin production triggered by IL-4 and TNF-alpha.

Sato T, Saito R, Jinushi T, Tsuji T, Matsuzaki J, Koda T, Nishimura Si, Takeshima H, Nishimura T.

Biochem Biophys Res Commun. 2004 Feb 6;314(2):468-75.

PMID:
14733929
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk